Shanghai Pharmaceuticals Holding Co.,Ltd. (SH PHARMA) has announced that its board of directors approved the company's participation in establishing the Shanghai Biopharmaceutical Phase II Fund on July 17, 2026.

The company, acting as a limited partner, plans to contribute 300 million yuan to the fund. Other partners include Shanghai Pharmaceutical Group (300 million yuan), SDIC Pioneer (450 million yuan), the Pudong Leading Area Fund (100 million yuan), Pudong Life Sciences (100 million yuan), the Guotai Junan Science and Innovation No. 1 Fund (100 million yuan), Beijing Qianyu (80 million yuan), Junshi Bio (50 million yuan), Shanghai Industrial Capital (19 million yuan, as general partner), and Shanghai Industrial Management Consulting (1 million yuan, as general partner).

Strategic Rationale for Participation

The company's involvement in establishing this fund holds significant strategic importance for the development of Shanghai's biopharmaceutical industry and for the company's own high-quality growth trajectory.

Fund's Intended Role

The Shanghai Biopharmaceutical Phase II Fund is designed to serve as a crucial instrument for advancing the company's innovation framework and its "Big BD" strategic objectives. Its purpose is to create an integrated internal ecosystem that spans multiple collaborative dimensions, including discovery, translation, and implementation.

Furthermore, the fund is expected to provide the company with a high-quality pipeline of early-stage projects. This approach is intended to effectively manage investment risks, enable precise supplementation of the research and development pipeline, and systematically enhance the efficiency of clinical translation.